



# Financial Tear Sheet

## Corporate Profile

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. In August 2018, Ovid announced that STARS, an international, double-blind, placebo-controlled, randomized Phase 2 clinical trial in adults and adolescents with Angelman syndrome, met its primary endpoint of safety and tolerability.

## Stock Performance

### OVID (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$1.80</b>
Change (%)	<b>▼ 0.05 (2.70%)</b>
Volume	444,612
52 Week High	\$11.45
52 Week Low	\$1.72
Market Cap	\$45,610,111
Rolling EPS	-1.65
PE Ratio	0
Shares Outstanding	24,654,114

Data as of February 21, 2019 12:37 p.m. ET



## Recent Headlines

February 20, 2019

Ovid Therapeutics Announces Pricing of \$30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock

---

February 19, 2019

Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

---

January 4, 2019

Ovid Therapeutics Outlines 2019 Clinical and Business Priorities

---

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
February 19, 2019	424B5
February 19, 2019	424B5
February 19, 2019	8-K
February 14, 2019	SC 13G

---

## Corporate Governance

Jeremy Levin, D.Phil., MB BChir	Chairman of the Board of Directors
------------------------------------	--

---

Data provided by Nasdaq. Minimum 15 minutes delayed.

---

© Ovid Therapeutics.. All rights reserved.